Imagine a 3D-printed temporary mold that holds a small piece of a patient's own fat in place. Over a few months, the body fills this mold with natural tissue to rebuild the breast. Eventually, the mold completely dissolves on its own, leaving only the patient's own natural breast behind without any permanent foreign plastic.
Current breast reconstruction requires multiple surgeries, carries risks of silicone implant complications, and is often too expensive or complex for 80% of eligible patients.
A 3D-printed bioprosthesis consisting of a resorbable scaffold and shell that regenerates autologous adipose tissue.
If you are a medical device producer dealing with the risks and long-term complications of silicone implants — this project developed a 3D-printed resorbable bioprosthesis that allows natural reconstruction and fully degrades after 18 months.
If you are a clinic operator dealing with high costs and multiple surgery stages for mastectomy patients — this project developed a device that enables reconstruction in a single surgery, reducing costs per patient by 30-60%.
If you are a polymer supplier dealing with the demand for high-performance bioabsorbable materials — this project developed a use case for 3D-printed medical grade biopolymers that support adipose tissue regeneration over 3-6 months.
The MATTISSE bioprosthesis leads to an overall cost per patient that is 30-60% lower than current autologous techniques.
Lattice Medical intends to recruit a commercial team to implement a marketing plan with the goal of supporting 40,000 women by 2030.
Based on available project data, the technology is developed by Lattice Medical, but specific patent or licensing terms are not detailed.
The project aims to perform mandatory clinical studies to obtain the CE mark for the EU market.
The bioprosthesis is designed to be fully degradable after 18 months.
The project is led by a single SME, Lattice Medical (FR), which holds 100% of the industry ratio. This lean structure suggests a highly focused commercial drive, as the company is directly managing the transition from clinical validation to market launch without the complexity of a large academic consortium.
Contact Lattice Medical (France) regarding the MATTISSE bioprosthesis commercialization
Contact us to find similar bioabsorbable 3D-printing technologies for medical applications.
